Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

• Status: Recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Fudan University
• Treatments: Sirolimus

Criteria

Inclusion Criteria:

• Participant clinically or pathologically diagnosed with KHE, TA or complicated superficial vascular anomolies involving lymphatic components.

1. The case is initial, with a relatively limited superficial lesion.

2. The participant has residual surface lesions after oral medication.

• Participant with no use of other medication or surgical treatment

• Participant with detailed medical records of the disease at the time of screening

• Participant with signed and dated informed consent from the guardian(s)

Exclusion Criteria:

• Participants with Kasabach-Merritt Phenomenon, with platelets <50×10 9 /L.

• Participants with general disease such as hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency.

• Participants with other hematological diseases or solid tumor.

• Participants allergic to sirolimus or dressing.